From the Food and Drug Administration |

New First-Line Therapy for Colorectal Cancer

Jane E. Henney, MD
JAMA. 2000;284(1):33. doi:10.1001/jama.284.1.33.
Text Size: A A A
Published online


The FDA has approved a new indication for irinotecan hydrochloride injection (Camptosar; Pharmacia & Upjohn Inc, Kalamazoo, Mich) as first-line therapy in combination with 5-fluorouracil and leucovorin to treat metastatic colorectal cancer. The approval was based on the results of two multicenter, randomized controlled trials in patients with metastatic cancer of the colon or rectum.

One study was conducted in Europe with 385 patients who were randomized to receive 5-fluorouracil and leucovorin with or without irinotecan. One regimen consisted of leucovorin, 200 mg/m2 given over 2 hours, and 5-fluorouracil as a 400 mg/m2 bolus followed by 600 mg/m2, administered intravenously over 22 hours, given every 2 weeks. Patients randomized to the irinotecan group also received 180 mg/m2 of irinotecan before receiving leucovorin on the first day of each 14-day cycle. The study demonstrated statistically significant improvement in survival in the irinotecan group (median, 17.4 vs 14.1 months, P<.05).

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario